A5002001005- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Renal and related cancers
- Genomics and Rare Diseases
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Prostate Cancer Treatment and Research
- Molecular Biology Techniques and Applications
- Innovative Teaching and Learning Methods
- PARP inhibition in cancer therapy
- Genetic factors in colorectal cancer
- Prostate Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Ear and Head Tumors
- Cardiac tumors and thrombi
- Cutaneous Melanoma Detection and Management
- Esophageal Cancer Research and Treatment
- Protein Degradation and Inhibitors
Regeneron (United States)
2023-2025
Memorial Sloan Kettering Cancer Center
2008-2024
Kettering University
2020-2023
Minnesota State University Student Association
2016
Beth Israel Deaconess Medical Center
2009
Columbia University
2007
University of Michigan
2007
Abstract The utility of cancer whole genome and transcriptome sequencing (cWGTS) in oncology is increasingly recognized. However, implementation cWGTS challenged by the need to deliver results within clinically relevant timeframes, concerns about assay sensitivity, reporting prioritization findings. In a prospective research study we develop workflow that reports comprehensive 9 days. Comparison diagnostic panel assays demonstrates potential capture all reported mutations with comparable...
Abstract Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic relapse site. Subclonal...
TPS293 Background: Advanced mCRPC and metastatic ccRCC are urologic malignancies with poor prognoses, novel therapies that can improve long-term outcomes remain an unmet medical need. Prostate-specific membrane antigen (PSMA) is a validated therapeutic target for prostate cancer. It transmembrane protein enzymatic activity highly expressed by cancer cells neovasculature. Nezastomig (REGN5678) first-in-class, PSMA×CD28 co-stimulatory bispecific antibody (bsAb) facilitates T-cell mediated...
Elderly patients with muscle invasive bladder cancer often present treatment challenges due to concomitant comorbidities and psychosocial factors. This study examines patterns of in this population evaluates the impact these factors on overall survival a contemporary population.Common components geriatric assessment were reviewed 152 consecutive 70 years old or older presenting nonmetastatic from January 1995 December 2004 (median followup 41 months). Overall was evaluated using Kaplan-Meier...
Abstract Purpose The optimal management of central nervous system (CNS) relapse rhabdomyosarcoma (RMS) is unclear. We examined diagnosis, management, and outcomes patients with RMS developing CNS relapse. Methods Records 23 diagnosed between 1999 2016 were reviewed. Median age at presentation was 15 years (range, 1–34 years). High‐risk features initial as follows: 16 alveolar patients, 13 Stage IV, primary tumor in parameningeal locations. Results occurred a median 12 months 1–23 months)...
2503 Background: REGN7075, a first-in-class costimulatory bispecific antibody (bsAb), aims to restore immune sensitivity in traditionally non-immunoresponsive tumors by bridging CD28+ T cells with EGFR-expressing tumor (unlike other bsAbs that target CD3), facilitating T-cell activation through endogenous antigens. A first-in-human, open-label, Phase 1/2 study (NCT04626635) of REGN7075 (EGFR×CD28) ± cemi (anti–PD-1) pts advanced solid was conducted, consisting dose escalation (Part 1) and...
To examine the effect of radical nephrectomy (RN) with adjacent organ and structure resection on survival, as invasion organs in patients renal cell carcinoma (RCC) is rare.After institutional review board approval, we reviewed our database statistically analysed pathological stage T3 or T4 RCC who had RN a contiguous structure.We identified 38 2464 (1.5%) resection. The median (interquartile range) size mass was 11 (8-14) cm, follow-up 13 (5-33) months. Most (68%) were pT4 conventional...
Advances in molecular diagnostics have identified subsets of Ewing and Ewing-like sarcomas driven by variant translocations with unique biology. It is likely that patients these tumours will different clinical features therapeutic outcomes. Nevertheless, the management both locally within cooperative group trials depends on local pathological diagnosis. not known what diagnostic approaches are employed pathologists or if exact translocation commonly determined. In addition, it for deemed...
11503 Background: Prexasertib (PRX) is an inhibitor of CHK1, prevents DNA repair leading to mitotic catastrophe, and can enhance the activity DNA-damaging chemotherapy. Translocation driven sarcomas exhibit high levels replication stress have demonstrated susceptibility CHK1 inhibition in preclinical models. Desmoplastic small round cell tumor (DSRCT) rhabdomyosarcoma (RMS) are aggressive children, adolescents young adults for which novel therapies urgently required. Methods: We conducted a...
TPS11575 Background: Osteosarcoma is the most common primary bone tumor, occurring in children, adolescents, and young adults. In contrast to advances treatment for childhood cancers, there have been no significant improvements osteosarcoma outcomes past 40 years. Forty percent of patients will, at some point, advanced disease which has a very poor outcome with 5-year overall survival approximately 20%. Genomic alterations signatures associated sensitivity DNA damage response (DDR)...
Limited guidance exists on streamlining cancer therapy for adolescent and young adult (AYA) patients 15-39 years of age, as much the current data are extrapolated from pediatric or counterparts can differ significantly between two care models. Harmonization standard treatment approaches has potential to improve outcomes establish a foundation development future clinical trials. We present our experience harmonizing supportive regimens AYA with osteosarcoma receiving methotrexate,...
Multiple large-scale tumor genomic profiling efforts have been undertaken in osteosarcoma, however, little is known about the spatial and temporal intratumor heterogeneity how it may drive treatment resistance. We performed whole-genome sequencing of 37 samples from eight patients with relapsed or refractory osteosarcoma. Each patient had at least one sample a primary site metastatic relapse site. identified subclonal copy number alterations all but patient. observed that five patients,...
You have accessJournal of UrologyDiscussed Poster, Tuesday, May 23, 2006, 1:00 - 4:00 pm1 Apr 20061247: Performance Status is a Predictor Overall Survival in Elderly Patients with Muscle Invasive Bladder Cancer Alon Z. Weizer, Daya Joshi, Yingzi Zhang, Stephanie Daignault, Michael Kinnaman, James E. Montie, and Cheryl T. Lee WeizerAlon Weizer More articles by this author , JoshiDaya Joshi ZhangYingzi Zhang DaignaultStephanie Daignault KinnamanMichael Kinnaman MontieJames Montie LeeCheryl...
9070 Background: Melanoma has been reported to be susceptible immune control. Therefore, we hypothesized that concomitant suppression might impact the course of disease. Methods: We examined Beth Israel Deaconess Medical Center Cutaneous Oncology Program database for pts with at time melanoma diagnosis. The demographics and stage these were compared those in as a whole. In addition, 3 controls matched age, gender, tumor location identified each case disease outcome was between cases...
If you have never experienced this uprising on a cosmic scale, it can be difficult to reflect.It know where begin.How should navigate dynamic solar system?We no longer afford live with dogma.
If you have never experienced this uprising on a cosmic scale, it can be difficult to reflect.It know where begin.How should navigate dynamic solar system?We no longer afford live with dogma.
Abstract Objective: The osteosarcoma genome is characterized by high levels of genomic instability, however whether there pervasive ongoing or instability introduced an early catastrophic event, still unsettled. Methods: We performed 30-80x whole sequencing (WGS) 37 tumor samples from 8 patients with relapsed refractory osteosarcoma. Each patient had at least one sample a primary site and metastatic relapse site. A set confidence single nucleotide variants (SNV), copy number alterations...
<div>Abstract<p>Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic...
<p>Supplementary Figures</p>
<div>Abstract<p>Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic...